By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Esperion Therapeutics, Inc. 

3621 S. State Street
695 KMS Place
Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-332-0506 Fax: 734-332-0516

Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including atherosclerosis, as they relate to high density lipoprotein cholesterol, "HDL-C", also known as the "good" cholesterol.

The technology platform for Esperion is based upon the Reverse Lipid Transport (RLT) pathway. The RLT pathway is responsible for removing excess cholesterol and other lipids from arterial walls and other tissues for transport to the liver and elimination from the body. The Company's product candidates work by stimulating the RLT pathway through the enhancement of key HDL properties, which may result in improved vascular structure and function. Esperion is focusing its efforts on developing both acute and chronic therapies for cardiovascular and metabolic diseases.

Esperion was founded in 1998 by, among others, members of the Warner-Lambert/Parke-Davis (now Pfizer) team that discovered and developed atorvastatin, the highly successful multibillion-dollar drug. Since that time, an additional group of exceptional scientists and specialists has joined the Company. Many of these individuals have been instrumental in the discovery, development and commercialization of several of the pharmaceutical industry's most successful therapies. It is this combined team that makes Esperion a leading enterprise in HDL drug discovery and research.

Key Management:

  • Roger Newton, Ph.D.
    President and CEO
  • Timothy Mayleben
    Chief Operating Officer and CFO

    Last Updated: 01-18-05

    Key Statistics

    Ownership: Public

    Web Site: Esperion
    Symbol: ESPR

  • Industry

    Company News
    Esperion (ESPR) Prices Public Offering Of Common Stock 8/10/2017 11:11:24 AM
    Esperion (ESPR) Stock Gains On Strong Phase II Data 8/8/2017 8:33:06 AM
    Esperion (ESPR) Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results 8/8/2017 8:23:37 AM
    Esperion (ESPR) To Provide Bempedoic Acid Franchise Development Program Updates And Second Quarter Financial Results 8/3/2017 11:24:33 AM
    Esperion (ESPR) Announces Initiation Of Phase II Study Of Bempedoic Acid Added-On To A PCSK9 Inhibitor 7/27/2017 11:00:48 AM
    Esperion (ESPR) Announces FDA Confirmation Of Regulatory Pathway To Approval For The Combination Of Bempedoic Acid And Ezetimibe 6/27/2017 12:44:39 PM
    If Esperion (ESPR) Wants To Market The Next Big Cholesterol Drug, It Will Take Strategy 6/23/2017 6:22:39 AM
    Esperion (ESPR) To Present At The JMP Securities 2017 Life Sciences Conference 6/15/2017 11:41:23 AM
    Esperion (ESPR) To Present At The Jefferies 2017 Global Healthcare Conference 6/1/2017 2:21:03 PM
    Esperion (ESPR) Provides Update On Common Stock Trading Activity 5/22/2017 10:44:01 AM